New hope for CML patients: asciminib combo trial launches
NCT ID NCT07538401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests asciminib, a newer targeted drug, alone or with dasatinib, in 45 adults with chronic myeloid leukemia (CML) whose first treatment stopped working. The goal is to see if this approach can reduce cancer cells to very low levels within 24 weeks. Patients with high-risk mutations get the combination; others get asciminib alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- asciminib (with or without dasatinib)
- What this could lead to
- If successful, this could offer a more effective second-line treatment option for people with CML whose first therapy stopped working.
- What could go wrong
- This is a small, early-phase trial (45 people) with no results yet. The drug combination may not work better than existing options and could have side effects like fluid retention or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) IN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.